Metabolic syndrome and antipsychotics: associated factors
Research type
Research Study
Full title
Metabolic syndrome in patients treated with antipsychotics: Exploring associated modifiable risk factors
IRAS ID
229330
Contact name
Nilamadhab Kar
Contact email
Sponsor organisation
Black Country Partnerhsip NHS Foundation Trust
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
It is well known that hypertension, high blood sugar, high cholesterol and obesity are common in the population and are the cause of increased morbidity and mortality.
When all these disorders are present together, known as metabolic syndrome, in an individual, the clinical concerns becomes extremely high.
Studies show that people with severe mental illness have lower life expectancy than general public. This is mostly due to cardiovascular and cerebrovascular morbidity.
While illnesses like schizophrenia are associated with diabetes and cardio-metabolic disorders, it is well known that psychotropic medications also contribute to weight gain and problems in glucose metabolism. In addition, life style factors of the persons with mental illness may influence the prevalence of these metabolic disorders.
There are many studies which suggest high prevalence of metabolic syndrome in patients with schizophrenia, but there is scant information on patients with other diagnosis who are receiving antipsychotic medications.
Many mentally ill patients on antipsychotic medications do not develop metabolic disorders or have metabolic syndrome. Understandably many factors influence these outcomes; some of which could be modifiable e.g. diet, exercise and substance abuse. There is hardly any study about the metabolic syndrome in a naturalistic scenario comparing various clinical and life style factors.
It is intended to study the prevalence of metabolic syndrome in patients receiving different antipsychotics for various diagnoses and study the factors contributing to it, to highlight the modifiable, preventable factors that may be useful for individual patients.
In cross sectional study, we will collect and analyse the relevant information which are already available in patients’ notes following routine clinical work. We will clarify the history, side effects and quality of life. Patients and their clinicians will be informed about the results individually and in summary at the end of the study.REC name
HSC REC A
REC reference
17/NI/0126
Date of REC Opinion
13 Jul 2017
REC opinion
Further Information Favourable Opinion